Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01505972
Other study ID # NR13002404_1
Secondary ID
Status Completed
Phase N/A
First received December 8, 2011
Last updated January 6, 2012
Start date March 2011
Est. completion date September 2011

Study information

Verified date January 2012
Source Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology
Contact n/a
Is FDA regulated No
Health authority Poland: Ethics Committee
Study type Interventional

Clinical Trial Summary

The attendance rate to population based primary screening colonoscopy within NordICC trial (The Nordic-European Initiative on Colorectal Cancer, NCT00883792) in Poland is roughly 33%. The aim of this study is to compare the effect of two different time schedules for sending invitations and reminding letters to a pre-specified colonoscopy appointment. 1,600 screening naive men and women 55 to 64 years of age are randomly assigned in a 1:1 ratio to receive invitation and reminder 6 and 3 weeks (SIX and THREE group) or 4 and 2 weeks (FOUR and TWO group) prior to pre-specified screening colonoscopy appointment date. Outcome measures are participation in screening colonoscopy within 6 months from the date of invitation, response and acceptance rate before sending a reminder. The study is powered to detect 7% difference in participation in screening colonoscopy.


Recruitment information / eligibility

Status Completed
Enrollment 1600
Est. completion date September 2011
Est. primary completion date September 2011
Accepts healthy volunteers No
Gender Both
Age group 55 Years to 64 Years
Eligibility Inclusion criteria:

Individuals aged 55-64 years living in Warsaw area randomly drawn from Population Registry and randomized to the screening arm of the NordICC trial.

Exclusion criteria:

- Resident abroad

- Return of unopened letter of invitation and/or reminder (address unknown)

- Message from neighbour/family/post office on death of screenee (not updated in Population Registry).

Exclusion criteria for colonoscopy:

- Individuals with previous colorectal surgery (resections, enterostomies)

- Individuals in need of long-lasting attention and nursing services (somatic or psychosocial, mental retardation).

- On-going cytotoxic treatment or radiotherapy for malignant disease

- Severe chronic (longer than trial duration) cardiac (NYHA III-IV)or lung disease

- Lifelong anticoagulant therapy with Warfarin

- A coronary event requiring hospitalization during the last 3 months

- A cerebrovascular event during the last 3 months

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research


Related Conditions & MeSH terms


Intervention

Other:
Six and three time schedule
Invitation letter sent 6 weeks and reminder 3 weeks before a pre-specified screening colonoscopy appointment date.
Four and two time schedule
Invitation letter and reminder sent 4 and 2 weeks before pre-specified screening colonoscopy appointment date.

Locations

Country Name City State
Poland Center of Oncology Institute and the Maria Sklodowska-Curie Warsaw W.K.Roentgena

Sponsors (2)

Lead Sponsor Collaborator
Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology The National Centre for Research and Development, Poland

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Participation rate Percentage of attenders to screening colonoscopy. 6 months from the date of sending invitation letter No
Secondary Acceptance rate in SIX &THREE group Percentage of invitees who agreed (by phone or letter) to participate in screening colonoscopy before sending a reminder 3 weeks from the date of sending invitation letter No
Secondary Acceptance rate in FOUR&TWO group Percentage of invitees who agreed (by phone or letter) to participate in screening colonoscopy before sending a reminder 2 weeks from the date of sending invitation letter, respectively No
Secondary Response rate in SIX&THREE group Percentage of invitees who responded (by phone or letter) before sending a reminder 3 weeks from the date of sending invitation letter No
Secondary Response rate in FOUR&TWO group Percentage of invitees who responded (by phone or letter) before sending a reminder 2 weeks from the date of sending invitation letter No
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A